Pertussis Vaccine Market Report 2026

The pertussis vaccine market size has grown steadily in recent years. It will grow from $5.65 billion in 2025 to $5.82 billion in 2026 at a compound annual growth rate (CAGR) of 2.9%. The growth in the historic period can be attributed to high childhood immunization coverage, government-led national vaccination programs, historical outbreaks of whooping cough, inclusion of pertussis vaccine in routine immunization schedules, availability of whole-cell vaccines.

The pertussis vaccine market size is expected to see steady growth in the next few years. It will grow to $6.82 billion in 2030 at a compound annual growth rate (CAGR) of 4.1%. The growth in the forecast period can be attributed to rising awareness of adult pertussis vaccination, increasing maternal immunization recommendations, advancements in vaccine safety and efficacy, expansion of healthcare access in emerging economies, growth in combination vaccine development. Major trends in the forecast period include rising adoption of acellular pertussis vaccines, increasing focus on booster immunization programs, expansion of combination vaccines including pertussis, growing adult and maternal pertussis vaccination, strengthening government immunization initiatives.

Rising childbirth rates are expected to drive the growth of the pertussis vaccine market in the coming years. Childbirth refers to the process of giving birth to a child, marking the end of pregnancy during which the fetus develops in the mother’s uterus and the beginning of life outside the womb. The pertussis vaccine is primarily administered to children to protect them from whooping cough and other serious, potentially life-threatening illnesses. For instance, in January 2023, according to a report published by the Centers for Disease Control and Prevention, a US-based national public health organization, the United States saw a 1% increase in registered births, totaling 3,664,292 compared to 2022. Therefore, rising childbirth rates are driving the growth of the pertussis vaccine market.

Major companies operating in the pertussis vaccine market are focusing on developing advanced immunization solutions and obtaining regulatory approvals to enhance maternal and infant protection against whooping cough. These initiatives aim to improve vaccine accessibility, expand recommended use during pregnancy, and reduce pertussis-related complications among newborns. For instance, in January 2023, Sanofi S.A., a France-based biopharmaceutical company, received U.S. FDA approval for the expanded use of its Adacel (Tdap) vaccine during the third trimester of pregnancy, allowing maternal immunization to help protect infants under two months of age, who are at the highest risk of severe pertussis infection. This approval enables healthcare providers to immunize pregnant individuals so that protective antibodies are transferred to the newborn before birth, providing early-life protection until the infant can receive their own vaccinations.

In June 2025, BioNet-Asia Co. Ltd., a Thailand-based vaccine biotech group with headquarters in France, partnered with PT Bio Farma to develop and distribute a combined TdaP vaccine (tetanus, diphtheria, and acellular recombinant pertussis) across the ASEAN region. These partnerships aim to strengthen regional healthcare by improving access to essential vaccines, enhancing local manufacturing capabilities, and increasing ASEAN’s preparedness against infectious diseases. Perseroan Terbatas Bio Farma (Persero) is an Indonesia-based company that provides vaccines to protect against pertussis (whooping cough).

Major companies operating in the pertussis vaccine market are Pfizer Inc., Merck & Co. Inc., GlaxoSmithKline plc, Sanofi Pasteur SA, CSL Limited, Serum Institute of India, Biological E. Limited, Bharat Biotech International Limited, Panacea Biotec Limited, PT Bio Farma, Walvax Biotechnology Co. Ltd., Beijing Minhai Biotechnology Co. Ltd., Wuhan Institute of Biological Products, Changchun Changsheng Life Sciences, Changsheng Bio-Technology Co. Ltd., Chiron Corporation, Sinovac Biotech Ltd., Takeda Pharmaceutical Company, Novartis AG, Johnson & Johnson.

North America was the largest region in the pertussis vaccine market in 2025. The regions covered in the pertussis vaccine market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the pertussis vaccine market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have created cost pressures in the pertussis vaccine market by increasing prices of imported active pharmaceutical ingredients, biologics raw materials, and specialized manufacturing equipment. these impacts are most pronounced in acellular vaccine production, combination vaccines, and supply chains serving asia-pacific, europe, and north america, where cross-border sourcing is common. pediatric and combination vaccine segments face margin pressure due to limited pricing flexibility in public immunization programs. however, tariffs are also encouraging localized manufacturing, regional supply chain resilience, and domestic vaccine production investments, supporting long-term market stability.

The pertussis vaccine market research report is one of a series of new reports that provides pertussis vaccine market statistics, including pertussis vaccine industry global market size, regional shares, competitors with a pertussis vaccine market share, detailed pertussis vaccine market segments, market trends and opportunities, and any further data you may need to thrive in the pertussis vaccine industry. This pertussis vaccine market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The pertussis vaccine is a vaccine that provides protection against whooping cough (pertussis), a highly contagious respiratory disease caused by the bacterium Bordetella pertussis. It is designed to stimulate the immune system to produce protective antibodies against the pertussis bacterium, thereby reducing the risk of infection and its associated symptoms.

The main products of the pertussis vaccine are the DTaP (diphtheria, tetanus, and acellular pertussis) vaccine and the TDaP (tetanus, diphtheria, and pertussis) vaccine. The DTaP vaccine, also known as the DTP vaccine, is a combination vaccine that protects against three serious bacterial infections: diphtheria, tetanus, and pertussis (whooping cough). These vaccines are available in whole-cell and acellular forms and are administered to children, adults, and infants by various end users, including vaccination centers, hospitals, and clinics.

The pertussis vaccine market consists of sales of adacel, daptacel, infanrix, kinrix, pediarix, pentacel and quadracel. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.